Identification of Malignant Tumors from the Perspective of “Yin and Yang”

LU Shen; XUE Jiao; ZHANG Xiaoying; WANG Xiongwen

doi:10.13288/j.11-2166/r.2018.21.008

您当前的位置：

首页 >

文章列表页 >

Identification of Malignant Tumors from the Perspective of “Yin and Yang”

更新时间：2021-11-10

- Identification of Malignant Tumors from the Perspective of “Yin and Yang”
- Journal of Traditional Chinese Medicine Vol. 59, Issue 21, Pages: 1828-1831(2018)
- 作者机构：
  
  1. 广州中医药大学第一临床医学院
  2. 广州中医药大学第一附属医院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2018.21.008
  CLC： R273
- Published：2018
- 稿件说明：
移动端阅览
[1]卢燊,薛娇,张晓莹,王雄文.从“阴阳”视角辨识恶性肿瘤[J].中医杂志,2018,59(21):1828-1831.

LU Shen, XUE Jiao, ZHANG Xiaoying, et al. Identification of Malignant Tumors from the Perspective of “Yin and Yang”[J]. Journal of Traditional Chinese Medicine2018, 59(21): 1828-1831.
[1]卢燊,薛娇,张晓莹,王雄文.从“阴阳”视角辨识恶性肿瘤[J].中医杂志,2018,59(21):1828-1831. DOI： 10.13288/j.11-2166/r.2018.21.008.

LU Shen, XUE Jiao, ZHANG Xiaoying, et al. Identification of Malignant Tumors from the Perspective of “Yin and Yang”[J]. Journal of Traditional Chinese Medicine2018, 59(21): 1828-1831. DOI： 10.13288/j.11-2166/r.2018.21.008.

摘要

恶性肿瘤具有"体阴而用阳"的性质和致病特征

核心病机是阴阳失调。恶性肿瘤的辨证应以阴阳辨证为纲领

需注意局部肿瘤辨证与人体整体的抗病反应相结合。调和阴阳是治疗总则

对于早期的患者可根据局部辨证结果对恶性肿瘤以"损其体、毁其用"

有全身症状的患者应以整体辨证为主

兼顾局部辨证

以此选定主方

然后根据患者合病、并病的情况进行合方加减。

Abstract

Malignant tumor itself is a pathogenic factor

it has such nature and pathogenic characteristic as"body yin and effect yang". The core pathogenesis is yin and yang disorders. The syndrome differentiation of malignant tumors should base on the syndrome differentiation of yin and yang. It is necessary to pay attention to the combination of local tumors differentiation and the overall human disease resistance. The reconciliation of yin and yang is the general principle of treatment. For the early stage patients

the results of local differentiation may be used to"damage the tumor body and destroy its effect". For patients with systemic symptoms

we should determine the main decoction by focusing on overall syndrome differentiation

supplemented by local syndrome differentiation. Then we could modify the decoction on the basis of simultaneous disease and following disease.

关键词

Keywords

references

查看原文

Views

486

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pathogenesis and Prevention Strategies of Hypercoagulable State in Malignant Tumors Based on the Theory of "Sweet-Flavored Medicinals Retaining and Restoring Body Fluid"

Pathogenesis，Differentiation and Treatment of Pre-Metastatic Niche in Malignant Tumors Based on the Theory of "Toxin Accumulation Damaging Yin"

Analysis of the Distribution of Traditional Chinese Medicine Syndrome Elements and Influencing Factors in Patients with Immune-Related Adverse Events from Malignant Tumors： A Retrospective Study Based on Propensity Score Matching

Current Status and Optimization Strategies for Investigator Initiated Trial on Traditional Chinese Medicine in the Treatment of Malignant Tumors Conducted by Western Medicine Institutions

Discuss the Preventive and Treatment for Immune-Related Adverse Events of Malignant Tumors Based on Simultaneous Treatment of Qi and Fire

Related Author

LIU Zhaidong

QIN Ruyu

SHI Yunxuan

SUN Yuwei

KONG Weiyang

CHENG Zixuan

WANG Yong

ZHANG Yao

Related Institution

The Affiliated Hospital of Shandong University of Traditional Chinese Medicine

First Clinical Medical College，Shandong University of Traditional Chinese Medicine

Fudan University Shanghai Cancer Center

Pulmonary Oncology Clinical Medicine Center，Shanghai Chest Hospital，Shanghai Jiao Tong University School of Medicine

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine，Shanghai University of Traditional Chinese Medicine

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰